Neximmune IncOTC Pink - Limited Information:NEXI
- LAST PRICE0.3300
- TODAY'S CHANGE (%)0.0871 (35.8752%)
- Bid / Lots0.3000/ 78
- Ask / Lots0.4099/ 25
- Open / Previous Close0.3000 / 0.2429
- Day Range
- 52 Week Range
- Volume3,967
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NEXI |
|---|---|---|
| 10:06 ET | 967 | 0.3 |
| 10:22 ET | 400 | 0.3 |
| 10:33 ET | 300 | 0.3 |
| 12:33 ET | 1000 | 0.32 |
| 01:08 ET | 950 | 0.4 |
| 01:09 ET | 200 | 0.33 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neximmune Inc | 338.7K | 0.0x | --- |
LadRx Corp | 365.0K | -0.1x | --- |
GlobeStar Therapeutics Corp | 348.9K | -0.1x | --- |
TC Biopharm (Holdings) PLC | 332.8K | 0.0x | --- |
RespireRx Pharmaceuticals Inc | 292.3K | -0.1x | --- |
Propanc Biopharma Inc | 237.0K | 0.0x | --- |
Company Information
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Contact Information
- Headquarters
- 9119 Gaither RoadGAITHERSBURG, MD, United States 20878
- Phone
- 301-825-9810
- Fax
- 302-636-5454
Executives
- President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Corporate Secretary, Director
- Craig Jalbert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $338.7K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.4M |
Neximmune Inc does not pay a dividend. | |
Beta | 1.59 |
EPS | $-18.59 |
Book Value | $3.29 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
